Validation of the Bronchiectasis Severity Index in alpha-1 antitrypsin deficiency
PLOS One · 2026
DOI: 10.1371/journal.pone.0355956 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift PLOS One, 2026. Verfasst von Joshua De Soyza und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Health Sciences, University of Birmingham, Birmingham, United Kingdom. Hauptthemen laut MEDLINE: alpha 1-Antitrypsin Deficiency, Bronchiectasis, Severity of Illness Index. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the University of Birmingham and Vertex Pharmaceuticals.
Abstract (Originalsprache)
Bronchiectasis is increasingly recognised in patients with alpha-1 antitrypsin deficiency (AATD), yet prognostic tools validated in general bronchiectasis populations have not been specifically evaluated in this group. The Bronchiectasis Severity Index (BSI) is a widely used multidimensional score predicting mortality, hospitalisation, and exacerbations in all-cause bronchiectasis. This study aimed to validate the BSI in a cohort of patients with AATD-bronchiectasis. Clinical data were obtained from the Birmingham AATD registry. Patients with severe AATD genotypes and CT-confirmed bronchiectasis were included, while those with non-severe genotypes or alternative causes of bronchiectasis were excluded. BSI scores were calculated using available registry data with minor adjustments reflecting the limitations of cross-sectional data collection. Associations between BSI and mortality were assessed using Kaplan–Meier survival analysis and Cox proportional hazards models adjusted for COPD, smoking status, and sex. Secondary analyses evaluated associations between BSI and lung function decline (FEV 1 and KCO) and health-related quality of life (SGRQ). A total of 198 patients were included (mean age 54.3 ± 9.7 years; 53.5% male), the majority with the ZZ genotype (97.5%) and coexisting COPD (87.4%). Median BSI score was 5 (range 0–14). Mortality differed significantly across BSI severity groups (p < 0.001): estimated 1-year mortality was 1.1%, 7.4%, and 20.0% for mild, moderate, and severe disease respectively, while 4-year mortality was 5.7%, 23.7%, and 31.8%. In Cox regression analysis adjusted for COPD, smoking, and sex, BSI remained significantly associated with mortality (hazard ratio 1.13 per point increase; 95% CI 1.05–1.23; p = 0.002). BSI score was also associated with greater decline in gas transfer (KCO) (β = −0.22% per point per year; p < 0.001), but showed no significant association with FEV 1 decline or SGRQ score. The Bronchiectasis Severity Index is associated with mortality risk in patients with AATD-associated bronchiectasis, supporting its use as a prognostic tool in this population. These findings provide evidence that a severity score derived from all-cause bronchiectasis cohorts can be applied to AATD, although prospective validation in larger multicentre datasets is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Applied Health Sciences, University of Birmingham, Birmingham, United Kingdom.
- Department of Respiratory Medicine, University Hospitals Birmingham, Birmingham, United Kingdom.
ORCID-Profile: Joshua De Soyza, Anita Pye
Förderung
- the University of Birmingham and Vertex Pharmaceuticals
Zitieren
APA
De Soyza, J., Ellis, P., Spittle, D., Pye, A., & Turner, A. M. (2026). Validation of the Bronchiectasis Severity Index in alpha-1 antitrypsin deficiency. PLOS One. https://doi.org/10.1371/journal.pone.0355956
Vancouver
De Soyza J, Ellis P, Spittle D, Pye A, Turner AM. Validation of the Bronchiectasis Severity Index in alpha-1 antitrypsin deficiency. PLOS One. 2026. doi:10.1371/journal.pone.0355956
BibTeX
@article{DeSoyza2026,
author = {De Soyza, Joshua and Ellis, Paul and Spittle, Daniella and Pye, Anita and Turner, Alice M},
title = {Validation of the Bronchiectasis Severity Index in alpha-1 antitrypsin deficiency},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0355956}
}
EUVIMED